# Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00029003** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 90 (actual)

## Conditions studied

- Bronchoalveolar Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** gefitinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00029003
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00029003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00029003, "Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00029003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*